Galectin tumbles premarket

Shares of Galectin Therapeutics (NASDAQ:GALT) crater 46% premarket on robust volume in response to the company's webcast this morning. It was presenting data for its galactin inhibitor, GR-MD-02, as a treatment for fatty liver disease (NASH). Apparently, Slide 20 shows data that it has no effect on Galectin 3.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs